Friday, 11 April 2014
  3 Replies
  3.9K Visits
New information resources are available to support the introduction of IPV, including FAQs, fact sheets and a new polio position paper. Since mid-April 2013, core partners of the Global Polio Eradication Initiative and the GAVI Alliance have been focusing efforts on objective 2 of the Polio Endgame Strategic Plan, supporting countries to introduce IPV in preparation for the switch from trivalent OPV to bivalent OPV. Access the resources at: http://www.who.int/immunization/diseases/poliomyelitis/inactivated_polio_vaccine
9 years ago
·
#2806
Dear Editor, Thanks for sharing the resource. I am very happy that WHO resource talks of low cost IPV through intradermal route which would be of great benefit to low and middle income countries. Though the non availability of this low cost intradermal option is biggest challenge to WHO as companies would not like to offer low cost option to the masses. The talk of low median levels of seroconvertion in intradermal route needs further discussion as interference by maternal antibodies can not be ignored in there studies, as has been pointed out in below reference; http://www.nejm.org/doi/full/10.1056/NEJMoa0909383#t=articleResults I request researchers to do studies in children having no maternal antibodies to bring out the truth because intradermal antirabies vaccine is as effective as IM doses because there are no maternal antibodies to interfere in the patients for rabies. Thanks, Dr. Omesh Bharti, India [email protected] +91-9418120302
9 years ago
·
#2807
A fair amount of research is on-going on the adminsitration of IPV through the intra-dermal route and it is likely that solutions will soon be licensed. However, in the context of the current phase of the Polio Eradication and Endgame Strategic Plan, the introduction of one dose of IPV in the routine immunization programme of all OPV-only using countries by the end of 2015 , it is realistic to expect that most countries will /shoud adopt the approach to introduce one full IM dose so that they are not delayed in their introduction efforts. From a financial perspective, IPV is now available at much more affordable prices (see attached UNICEF price list) and the GAVI Alliance as well as the GPEI are providing substantial support to countries to help them introduce this vaccine, before the end of 2015 so we can be ready for the global withdrawal of type 2 OPV in the middle of 2016
9 years ago
·
#2808
Dear moderator, Until we force the companies to adopt low cost solutions like ID delivery through needle and syringe, we would not succeed as has been the experience with rabies vaccine, especially in India. Also, we should allow time for such experiments than succumb to the pressure of the multinationals to deliver early. If mOPV3 could be launched in India based on trials somewhere else, we should do the same for other vaccines. Inradermal rabies vacination is a classic example in India to learn the techtics of the multinationals and here is my paper on that, http://www.scirp.org/journal/PaperInformation.aspx?paperID=21524 Regards,
  • Page :
  • 1
There are no replies made for this post yet.